UniProtKB/Swiss-Prot P00747: Variant p.Asp472Asn

Plasminogen
Gene: PLG
Feedback?

Variant information Variant position:

472 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Aspartate (D) to Asparagine (N) at position 472 (D472N, p.Asp472Asn). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from medium size and acidic (D) to medium size and polar (N) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs4252125 [ dbSNP | Ensembl ]

Sequence information Variant position:

472 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

810 The length of the canonical sequence.
Location on the sequence:

KKCSGTEASVVAPPPVVLLP D VETPSEEDCMFGNGKGYRGK The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         KKCSGTEASVVAPPPVVLLPDVETPSEEDCMFGNGKGYRGK

Rhesus macaque                KKCSGTEGSVAAPPPVAQLPDAETPSEEDCMFGNGKGYRGK

Mouse                         KRCSETGGSVVELPTVSQEPSGPSDSETDCMYGNGKDYRGK

Rat                           KRCSETGGGVAESAIVPQVPSAPGTSETDCMYGNGKEYRGK

Pig                           KKCSETEQQVTNFPAIAQVPSVEDLSE-DCMFGNGKRYRGK

Bovine                        KKCSETPEQV---PAAPQAPGVENPPEADCMIGTGKSYRGK

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	20 – 810	Plasminogen
Chain	20 – 580	Plasmin heavy chain A
Chain	98 – 580	Plasmin heavy chain A, short form

Literature citations
Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system.
Petersen T.E.; Martzen M.R.; Ichinose A.; Davie E.W.;
J. Biol. Chem. 265:6104-6111(1990)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANT ASN-472; Submission
SeattleSNPs variation discovery resource;
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS LYS-57; GLN-133; HIS-261; TRP-408; ASN-472; VAL-494 AND TRP-523; Submission
Sottrup-Jensen L.; Petersen T.E.; Magnusson S.;
Cited for: PROTEIN SEQUENCE OF 20-810; VARIANT ASN-472; The primary structure of human plasminogen.
Sottrup-Jensen L.; Claeys H.; Zajdel M.; Petersen T.E.; Magnusson S.;
Cited for: PROTEIN SEQUENCE OF 95-580; 581-626; 657-700 AND 732-810; VARIANT ASN-472;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.